Putting the evidence side by side Here is the blunt comparison: AOD 9604: 2.6 kg weight loss in 12 weeks (best result), failed six clinical trials, development terminated Semaglutide: 15 to 17 percent body weight loss over 68 weeks, FDA approved, thousands of study participants, consistent results across multiple trials There is no way to frame this comparison that puts AOD 9604 on equal footing with semaglutide when it comes to clinical evidence
Your semaglutide clinician will help determine the most suitable option based on your medical profile, insurance coverage, and personal preference
This guide explains the general site-selection logic, why GHK-Cu is different from approved injectable drugs, and when to stop and get medical guidance
While NRF2 activates NADPH production through the upregulation of the pentose phosphate pathway, malic enzyme, and isocitrate dehydrogenase, NRF2 also supports cellular NADPH levels by suppressing NADPH-consuming processes
Your provider can adjust the dose, suggest bowel regimens, or arrange labs to check electrolytes and kidney function
MEDVi's structure, services, and results reflect this rising wave of wellness personalization and medical-grade convenience